In the streets of Mumbai and the pharmacies of the Global South, a quiet revolution is underway that should shame the corporate boardrooms of the West. Indian generic drugmakers have flooded the market with copies of semaglutide, the highly coveted weight-loss drug, at prices as low as $15 a month. This is a staggering rebuke to the 'Subscription Body' model favored by Western pharmaceutical giants, who seek to gatekeep human health behind exorbitant paywalls.

For too long, we have allowed the physical well-being of the person to be treated as a recurring revenue stream for the elite. While Amazon and Eli Lilly partner to deliver high-priced prescriptions to the wealthy via digital kiosks, the working poor of the world have been left to manage obesity and diabetes on their own. This market bifurcation is a moral failure that treats health as a luxury rather than a stewardship of the body.

These generic alternatives represent a triumph of Distributist principles. They break the monopoly of the few to serve the needs of the many. While we must remain vigilant about the safety of these medications, we should celebrate any movement that restores agency to the individual and frees the family from the predatory pricing of biotech behemoths. The body is the temple of the soul; it should not be owned by a corporation.